Skip to main content

HealthTech For Care and EIT Health renew their partnership for the organisation of HealthTech Innovation Days, reinforcing its European positioning through new collaborations with BIO Deutschland and BioWin.

These partnerships, which reinforce the international dimension of the HealthTech Innovation Days, will facilitate collaborations within the European health ecosystem with the aim of accelerating patient access to medical innovations.

Paris, 3 March, 2021 – Following the success of the second edition of the HealthTech Innovation Days, in October 2020, supported by high-level French and European institutions, the third edition aims to establish itself as the reference event for global players in the European health ecosystem. By joining forces around HealthTech For Care, they prove their common commitment to supporting and promoting access to healthcare for all and, more particularly, to new medical technologies and new medicines.

The HealthTech For Care endowment fund is renewing its partnership with the European Institute of Innovation and Technology in Health (EIT Health) for the third edition of the HealthTech Innovation Days on 4 & 5 October 2021. “With more than 250 members, EIT Health is the largest European consortium in the health sector and brings together all types of life science players from more than 20 countries. From the start, HealthTech For Care has had the ambition to make HTID an event in Paris which promotes access to all patients in life sciences technologies. The renewal of the partnership with EIT Health and the new collaborations with BIO Deutschland and BioWin are perfectly in line with our strategy. I am delighted with this European collaboration.said Maryvonne Hiance, President of HealthTech For Care.

With the support of the European Commission and the European Investment Fund (EIF), EIT Health has chosen to partner with HealthTech For Care to host its co-investment programme Venture Centre of Excellence (VCoE) members, and organise VCoE member-exclusive sessions at HealthTech Innovation Days thereby establishing the event as a key milestone for health investment.

The Venture Centre of Excellence (VCoE) is a pan-European open innovation programme, created by EIT Health and the EIF, benefitting from a EUR 150m financial support from the European Commission, as announced during HTID 2020. The programme is expected to catalyse up to EUR 2 billion of investment in life sciences over the next 15 years. The VCoE will strengthen the collaboration and investment capacities of its members, thereby supporting cutting-edge technologies, commercialisation and the scale-up of products and services in the European ecosystem.

We look forward to the renewal of this partnership as well as the collaboration with other key players who contribute to making HealthTech Innovation Days a leading event in Europe for health innovation stakeholders. Our commitment to this collaboration is made clear by the VCoE’s decision to hold an exclusive member event during HealthTech Innovation Days 2021, we thereby hope to facilitate and strengthen relationships between corporates and academics selected by EIT Health which have subscribed to the programme, and the venture capital companies selected by the European Investment Fund.“. Jean-Marc Bourez Managing Director of EIT Health France and Head of the Venture Centre of Excellence.

In order to strengthen HealthTech For Care’s role as a European General Interest Endowment Fund, HealthTech For Care has signed two new collaborations: BIO Deutschland, the German Biotechnology Association that currently has over 340 members and BioWin, the health competitiveness cluster in Wallonia with 249 members. These collaborations show a common willingness on the part of several European clusters to collaborate together and accelerate innovation in health and make care more quickly accessible to patients.

The Corona crisis has once again made it very clear that research and development for our health can only bear fruit through collaboration. We at BIO Deutschland are therefore pleased to join forces with HealthTech For Care to strengthen European exchange and thus bring biotech innovations faster to society.Oliver Schacht, President of BIO Deustchland.

Through this partnership with HealthTech For Care, BioWin intends to consolidate its strategy and strengthen the European reach of this initiative. This partnership is at the heart of BioWin’s mission to accelerate innovation to meet the public health challenges of tomorrow.Sylvie Ponchaut, Managing Director, BioWin.

For more information:

About HealthTech For Care

The HealthTech For Care Endowment Fund is designed to support and promote access to care for all and, in particular, new medical technologies and drugs. The missions of the endowment fund are organized around three main areas: supporting the development of the entire healthcare ecosystem, accelerating the development of innovative therapies and medicines, and promoting better access for patients to the healthcare system in France and Europe. The governance of HealthTech For Care brings together Maryvonne Hiance, Elsy Boglioli, David Caumartin, Pierre Courteille, Eric Falcand, Marc Le Bozec, Cédric Moreau, Franck Mouthon, Christian Pierret and Christian Policard.

About EIT Health

Europe faces a turning point in health. An ageing population, the rising burden of chronic disease, and growing multi-morbidity are all placing pressure on health systems across Europe.
EIT Health is a vast, vibrant community of world leading health innovators backed by the European Union. Working across borders, our network connects approximately 150 world-class partner organisations, as well as entrepreneurs, start-ups and SMEs from the worlds of business, research, education and healthcare delivery. Our aim is to answer the biggest health challenges Europe faces and we believe that life changing innovation happens when these worlds meet and collaborate. That’s why we call this the ‘knowledge triangle’.From our headquarters in Munich, six regional Innovation Hubs and InnoStars cluster, which brings together organisations from regions in which the overall pace of innovation is more moderate, we provide an ecosystem in which fresh thinking can thrive. Our Regional Innovation Scheme further expands our presence in 13 countries across Central, Eastern and Southern Europe. EIT Health also leads the development of the EIT Hub in Israel, which connects innovators across Europe to other key thriving ecosystems beyond the EU.
EIT Health is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union. Our ambition is to enable people in Europe to live longer, healthier lives by transforming businesses and delivering new products and services that can progress healthcare in Europe and strengthen our economy.
EIT Health: Together for healthy lives in Europe.
For more information visit:


As the sector association of the biotechnology industry, BIO Deutschland has set itself the objective of supporting and promoting the development of an innovative economic sector based on modern biosciences. The Berlin-based association currently has over 340 members. It is run by a board of ten members consisting of CEOs and managing directors of biotechnology companies. The member companies and their experts are organised in working groups and networks that deal with a broad range of topics relevant for the sector. Using a wide range of political initiatives, BIO Deutschland lobbies for improvements to the legal parameters for innovative small and medium-sized enterprises. BIO Deutschland is member of the Federation of German Industries (BDI) and of the European Biotech association, EuropaBio, in Brussels. Additionally, the association is member of the US-biotech organization BIO and founding member of the International Council of Biotech Associations (ICBA).

About BioWin

The BioWin competitiveness cluster brings together all the innovation system players in Wallonia’s life science field, with the goal of stimulating regional economic redeployment. Initially, its role was largely focused on the development, selection and monitoring of collaborative research and innovation (R&I) projects involving universities, research centers, academic hospitals and industries. This role has expanded over time, and today, the cluster is also involved in implementing the sector’s industrial policy (industrial innovation and research, training, support for business growth, etc.). The purpose of this is to develop and anchor skills, knowledge and jobs. For more information visit

About HealthTech Innovation Days

Launched in 2019 by France Biotech and co-organized since 2020 by HealthTech For Care and EIT Health, the HealthTech Innovation Days (HTID) aim to accelerate the development of innovative European healthcare companies. This forum aims to facilitate collaborations and investments by bringing together international players in the health ecosystem. The 2nd edition was a great success with 780 participants, 150 innovative health companies (Biotech, Medtech, e-health), 300 global investors, 1000 private meetings organized, 19 conferences with international experts of the ecosystem. The HealthTech
Innovation Days are supported both by sponsors (international pharmaceutical companies, industrialists, investors, influential players in the world of HealthTech) and by institutional partners such as Emmanuel Macron, President of the French Republic, Thierry Breton, Commissioner of the European Commission, Agnès Pannier-Runacher, Minister Delegate to the Minister of Economy, Finance and Recovery, in charge of Industry and Alexandra Dublanche, Vice-President of the Regional Council of Ile-De-France. The third edition of the HealthTech Innovation Days 2021 will take place on October 4 and 5, 2021:

About France Biotech, Founder of HealthTech For Care

Founded in 1997, France Biotech is an independent association that brings together HealthTech entrepreneurs and their expert partners. It actively contributes to meet the many challenges of the HealthTech industry (i.e. companies’ financing, innovation-related taxes, regulatory and market access related issues) and offers concrete competition and solutions through its commissions and working groups. The goal is to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients.